Corium International, Inc. (CORI) Given Consensus Rating of “Buy” by Brokerages
Shares of Corium International, Inc. (NASDAQ:CORI) have been given an average recommendation of “Buy” by the ten analysts that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $13.17.
CORI has been the subject of a number of analyst reports. BidaskClub lowered Corium International from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Needham & Company LLC restated a “buy” rating and issued a $13.00 price objective on shares of Corium International in a research note on Sunday, September 17th. ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. HC Wainwright set a $15.00 price objective on Corium International and gave the company a “buy” rating in a research note on Friday, November 17th. Finally, Jefferies Group set a $10.00 price objective on Corium International and gave the company a “buy” rating in a research note on Sunday, October 29th.
Corium International (NASDAQ CORI) traded up $0.05 during midday trading on Thursday, reaching $10.81. The company had a trading volume of 118,200 shares, compared to its average volume of 183,431. Corium International has a twelve month low of $2.67 and a twelve month high of $12.32. The company has a quick ratio of 6.80, a current ratio of 7.04 and a debt-to-equity ratio of 1.89.
Several hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its stake in shares of Corium International by 33.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock worth $980,000 after acquiring an additional 22,285 shares during the period. California State Teachers Retirement System bought a new position in shares of Corium International during the 2nd quarter worth $263,000. State Street Corp bought a new position in shares of Corium International during the 2nd quarter worth $1,840,000. Stonepine Capital Management LLC bought a new position in shares of Corium International during the 2nd quarter worth $3,085,000. Finally, EAM Investors LLC bought a new position in shares of Corium International during the 2nd quarter worth $563,000. Institutional investors own 89.35% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Corium International, Inc. (CORI) Given Consensus Rating of “Buy” by Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/07/corium-international-inc-cori-given-consensus-rating-of-buy-by-brokerages.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.